MOTS-c
Also known as: Mitochondrial Open Reading Frame of the 12S rRNA-c
limited human dataNot FDA approvedResearch only
Published Dose Range
Low5 mg/dose
Typical5-10 mg 2-3x/week
High10 mg/dose
Mitochondrial-derived peptide. Limited human trials — dosing based on early clinical research.
Published Cycle Range
Short4 wks
Typical8 wks
Long12 wks
Limited long-term human data. Off-cycles recommended until more research is available.
Off-cycle: 4 weeks
Administration
Routessubcutaneous
Frequency2-3x per week
Preferred timingMorning, fasted
Early research suggests exercise-mimetic effects — morning dosing common.
Safety Profile
Contraindications
- • Active mitochondrial disease
Common side effects
- • Injection site reactions
- • Fatigue (reported in early users)
Serious risks
- • Long-term safety unknown — limited human data
Requires monitoring
- • Fasting glucose
- • HbA1c if metabolic goals
Pregnancy / breastfeeding
No data — consult clinician
Common Misconceptions
- Not a replacement for actual exercise — effects in humans are modest
Commonly Stacked With
AOD-96045-Amino-1MQ
Next Steps
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.